Epidemiology of HCV infection in the Central European region

Urbánek, Petr; Kristián, Pavol; Makara, Michael; Hunyady, Béla; Tomasiewicz, Krzysztof

doi:10.5114/ceh.2016.58849

Cited by 5 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genotype distribution in Poland seems to be similar to other Central-European countries. According to recent data, 80-85% of HCV infections in the Czech Republic are related to G1b, followed by HCV G3 (10-15%) [ 8 ]. In Slovakia G1b was identified as the most common, followed by genotype 3a and other genotypes (including 1a) [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…According to recent data, 80-85% of HCV infections in the Czech Republic are related to G1b, followed by HCV G3 (10-15%) [ 8 ]. In Slovakia G1b was identified as the most common, followed by genotype 3a and other genotypes (including 1a) [ 8 ]. In Hungary before 1993, among patients infected via blood and blood products, genotype 1b almost exclusively dominated, but due to the predominance of drug users genotype 1a recently became the most prevalent, and the remaining genotypes are G3 and G1b [ 8 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of HCV genotypes in Poland – the EpiTer study

Flisiak

Pogorzelska

Berak³

et al. 2016

ceh

Self Cite

View full text Add to dashboard Cite

The aim of the studyWas to assess current prevalence of hepatitis C virus (HCV) genotypes in Poland, including their geographic distribution and changes in a given period of time.Material and methodsData were collected with questionnaires from 29 Polish centers and included data of patients diagnosed with HCV infection between 1 January 2013 and 31 March 2016.ResultsIn total, data of 9800 patients were reported. The highest prevalence was estimated for genotype 1b (81.7%), followed by 3 (11.3%), 4 (3.5%), 1a (3.2%) and 2 (0.2%). Genotype 5 or 6 was reported in 6 patients only (0.1%). The highest prevalence of genotype 1 was observed in central (łódzkie, mazowieckie, świętokrzyskie), eastern (lubelskie) and southern (małopolskie, śląskie) Poland. The highest rate for genotype 3 was observed in south-western (dolnośląskie, lubuskie) and eastern (podlaskie, warmińsko-mazurskie and podkarpackie) Poland. Compared to historical data, we observed an increasing tendency of G1 prevalence from 72.0% in 2003 to 87.5% in 2016, which was accompanied by a decrease of G3 (17.9% vs. 9.1%) and G4 (9.0% vs. 3.1%).ConclusionsAlmost 85% of patients with HCV in Poland are infected with genotype 1 (almost exclusively subgenotype 1b), and its prevalence shows an increasing tendency, accompanied by a decrease of genotypes 3 and 4.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prevalence of HCV genotypes in Poland – the EpiTer study

Flisiak

Pogorzelska

Berak³

et al. 2016

ceh

Self Cite

View full text Add to dashboard Cite

show abstract

“…Historically, genotype 1b was the most prevalent genotype in the Czech Republic. More than 90% of treated individuals in the 1990s and 99% of patients indicated for liver transplantation for HCV infection from 1995 to 2013 were infected with genotype 1 (2,32,33). In addition, more than 50% of viremic patients in the Czech Republic have low pretreatment viremia, representing a positive predictive factor of response to treatment.…”

Section: Discussionmentioning

confidence: 99%

Chronic hepatitis C in the Czech Republic: Forecasting the disease burden

Fraňková

Urbánek

Husa

et al. 2019

Cent Eur J Public Health

Self Cite

View full text Add to dashboard Cite

Objective: Chronic HCV infection is associated with cirrhosis of the liver, hepatocellular carcinoma (HCC), and liver transplantation. HCV disease burden and the impact of new potent direct acting antivirals (DAAs) in the Czech Republic are unknown. Methods: Using a modelling framework, HCV disease progression in the Czech Republic was predicted to 2030 under the current standard of care treatment structure. In addition, two strategies to reduce the future burden of HCV infection were modelled: an incremental increase in treatment annually and WHO targets. Results: The number of viremic infected individuals in the Czech Republic is estimated to peak in 2026 (n = 55,130) and to decline by 0.5% by 2030 (n = 54,840). The number of individuals with compensated cirrhosis (n = 1,400), decompensated cirrhosis (n = 80), HCC (n = 70), and liverrelated deaths (n = 60) is estimated to more than double by 2030. Through aggressive increases in diagnosis and treatment, HCV related mortality may decrease by 70% by 2030. Conclusions: Disease burden associated with chronic HCV infection is projected to peak in the Czech Republic in 30-40 years. Assuming that the current portion of DAAs used remains constant, a significant reduction in HCV disease burden is possible through increased diagnosis and treatment through 2030. This analysis provides evidence in order to facilitate the development of national strategies for HCV care and management in the Czech Republic.

show abstract

“…The most prevalent HCV genotype in the Czech Republic is HCV GT 1b (80-85%) followed by GT 3 (mostly 3a, 10-15%) [44,45]. The data from Hungary suggest that GT 1b is present in more than 90% of infected persons [44,45].…”

Section: Discussionmentioning

confidence: 99%

New Epidemiologic Data Regarding Hepatitis C Virus Infection in Romania

Manuc

Preda

Popescu

et al. 2017

JGLD

View full text Add to dashboard Cite

Background & Aims: Literature data suggest that HCV genotype-1b is present in 93-99% of the Romanian patients infected with hepatitis C virus (HCV). We present the genotyping tests recently performed on patients with HCV and advanced fibrosis eligible for the Direct-Acting Antiviral (DAA) therapy, as well as the prevalence of these cases across Romania.Methods: The genotyping method was performed on 7,421 HCV patients with advanced fibrosis. The detection method was automatic real time PCR platform M2000 (Abbott). Every subject was introduced into a database including age, sex, county and address.Results: Genotype 1b was almost exclusively present: 7,392/7,421 (99.6%). Genotype 1b patients were 19.6% from Bucharest, 49% were males, with a median age of 60 years. Genotype non-1b was encountered in 29/7,421 subjects (0.4%), 62% were males, 69% from Bucharest and the median age was 52 years. Most of the subjects (75%) were in the 6th and 7th age decade. The prevalence of these cases varied significantly across Romanian counties: the highest was in Bucharest (61.3/105), Bihor (47/105), Iasi (46/105) and Constanța (43/105), and the lowest in Ilfov (2.8/105), Harghita (3.7/105), Covasna (5.4/105) and Maramureș (8.8/105) (p<0.001).Conclusions: Genotype 1b is encountered in 99.6% of patients with chronic hepatitis C and advanced fibrosis from Romania. The presence of genotypes non-1b is more common in Bucharest, in males and at a younger age. There are significant differences regarding the distribution of these cases across Romania: the highest rates are in Bucharest, Bihor, Iasi and Constanta.Abbreviations: BMI: body mass index; DAA: direct-acting antiviral agent; GT: genotype; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; IDU: intravenous drug users; MELD: model for end stage liver disease; NASH: non-alcoholic steatohepatitis; SVR; sustained virologic response.

show abstract

Epidemiology of HCV infection in the Central European region

Cited by 5 publications

References 9 publications

Prevalence of HCV genotypes in Poland – the EpiTer study

Prevalence of HCV genotypes in Poland – the EpiTer study

Chronic hepatitis C in the Czech Republic: Forecasting the disease burden

New Epidemiologic Data Regarding Hepatitis C Virus Infection in Romania

Contact Info

Product

Resources

About